Cochlear Ltd. (ASX:COH) today announced that it received FDA approval for extended applications of its Nucleus implants. Sydney, Australia-based Cochlear designed the Nucleus implants to treat unilateral hearing loss (UHL) and single-sided deafness (SSD). The implants were already FDA approved for those with moderate to profound bilateral sensorineural hearing loss. UHL is characterized by hearing loss […]
cochlear
MedTech 100 roundup: Stocks were practically unchanged last week
Despite plenty of ups and downs coming in the stock market for the medtech industry, there was hardly any movement from week to week. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.6 points at the end of last week (Aug. 21). Overall, medtech stocks saw […]
FDA approves Cochlear sound processor
Cochlear Ltd. (ASX:COH) announced today that it received FDA approval for three new products in its suite of implantable hearing technology. Lone Tree, Colo.-based Cochlear won approval for its Nucleus Kanso 2 sound processor, Nucleus 7 sound processor for Nucleus 22 implant recipients and Custom Sound Pro fitting software, according to a news release. Cochlear touts […]
Cochlear wins FDA approval to lower age to implant to 9 months
Cochlear Ltd. (ASX:COH) has received FDA approval to lower the age of cochlear implantation to nine months for children. The new approval lowers the age from the original 12 months for children with bilateral, profound sensorineural hearing loss. Cochlear implants have been FDA approved for use in children since 1990. “In light of all that has […]
Cochlear loses appeal over $268m in patent damages
The U.S. Court of Appeals for the Federal Circuit upheld a U.S. District Court decision that awarded $268 million in damages from Cochlear Ltd. (ASX:COH) to two competitors in a patent dispute. Yesterday’s ruling comes after several years of legal battles over the patents for hearing implants, and likely won’t be the end, as Cochlear is […]
FDA approves new MR-safe hearing device from Cochlear
Cochlear Ltd. (ASX:COH) today announced that it received FDA approval for its Cochlear Nucleus cochlear implant and its Nucleus 7 sound processor. The Nucleus Profile Plus implant is designed for safe use in MRI scans and offer easier access to 1.5 and 3.0 Tesla MRI scans without having to remove its internal magnet or use a […]
Cochlear joins $17m round for sleep apnea nueromod dev Nyxoah
Cochlear Ltd. (ASX:COH) has joined a $17.1 million (EU €15 million) funding round for Nyxoah to support the development and commercialization of its hypoglossal nerve stim therapy for treating obstructive sleep apnea. Australian hearing tech developer Cochlear lead the round, investing $14.7 million (EU €13 million). The round was also joined by several existing Nyxoah shareholders, […]
These 10 medtech companies care a lot about research
These 10 medical device companies spent the largest portion of their budgets on research and development. Here’s a look at what they produced. Each year, Medical Design & Outsourcing compiles a list of the top 100 medical device companies across the globe and ranks the companies based on annual revenue for the most recent fiscal […]
Cochlear launches Nucleus app for Android devices
Cochlear Ltd. (ASX:COH) said today it launched a Google (NSDQ:GOOG) Android compatible version of its Nucleus smart application designed for use with its Nucleus 7 sound processor. With the update, users of the Nucleus 7 with Android devices can control their hearing through the linked application, and will gain access to a number of new features previously […]
These 10 medtech companies care a lot about research
Among the world’s largest medtech companies, these 10 spent the largest portion of their budgets on research and development. So what have they produced? Every year, Medical Design & Outsourcing pulls financial regulatory filings and reaches out to major, companies in some cases to create a list of the 100 largest medical device companies in […]
